LT2979700T - Priešnavikinis agentas, turintis mažą irinotekano hidrochlorido hidrato dozę - Google Patents
Priešnavikinis agentas, turintis mažą irinotekano hidrochlorido hidrato dozęInfo
- Publication number
- LT2979700T LT2979700T LTEP14773638.3T LT14773638T LT2979700T LT 2979700 T LT2979700 T LT 2979700T LT 14773638 T LT14773638 T LT 14773638T LT 2979700 T LT2979700 T LT 2979700T
- Authority
- LT
- Lithuania
- Prior art keywords
- low dose
- antitumor agent
- including low
- agent including
- hydrochloride hydrate
- Prior art date
Links
- 239000002246 antineoplastic agent Substances 0.000 title 1
- 229960000779 irinotecan hydrochloride Drugs 0.000 title 1
- GURKHSYORGJETM-WAQYZQTGSA-N irinotecan hydrochloride (anhydrous) Chemical compound Cl.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 GURKHSYORGJETM-WAQYZQTGSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013066074 | 2013-03-27 | ||
| PCT/JP2014/058733 WO2014157444A1 (ja) | 2013-03-27 | 2014-03-27 | 低用量イリノテカン塩酸塩水和物を含有する抗腫瘍剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT2979700T true LT2979700T (lt) | 2018-12-27 |
Family
ID=51624406
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEP14773638.3T LT2979700T (lt) | 2013-03-27 | 2014-03-27 | Priešnavikinis agentas, turintis mažą irinotekano hidrochlorido hidrato dozę |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US9616081B2 (lt) |
| EP (1) | EP2979700B1 (lt) |
| JP (1) | JP6002835B2 (lt) |
| KR (1) | KR101848131B1 (lt) |
| AU (1) | AU2014245147B2 (lt) |
| CY (1) | CY1120990T1 (lt) |
| DK (1) | DK2979700T3 (lt) |
| ES (1) | ES2702911T3 (lt) |
| HR (1) | HRP20182145T1 (lt) |
| HU (1) | HUE041687T2 (lt) |
| LT (1) | LT2979700T (lt) |
| PL (1) | PL2979700T3 (lt) |
| PT (1) | PT2979700T (lt) |
| RS (1) | RS58067B1 (lt) |
| RU (1) | RU2668125C2 (lt) |
| SI (1) | SI2979700T1 (lt) |
| SM (1) | SMT201800677T1 (lt) |
| TR (1) | TR201819576T4 (lt) |
| TW (1) | TWI641374B (lt) |
| UA (1) | UA117581C2 (lt) |
| WO (1) | WO2014157444A1 (lt) |
| ZA (1) | ZA201507444B (lt) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013202947B2 (en) | 2012-06-13 | 2016-06-02 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
| US9717724B2 (en) | 2012-06-13 | 2017-08-01 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies |
| DK3199552T3 (da) | 2012-11-20 | 2020-03-30 | Sanofi Sa | Anti-ceacam5-antistoffer og anvendelser heraf |
| KR101847252B1 (ko) | 2013-03-27 | 2018-04-09 | 다이호야쿠힌고교 가부시키가이샤 | 이리노테칸염산염 수화물을 함유하는 항종양제 |
| HRP20230523T1 (hr) * | 2013-09-06 | 2023-08-04 | Taiho Pharmaceutical Co., Ltd. | Antitumorski agens i sredstvo za poboljšavanje antitumorskog efekta |
| US11318131B2 (en) | 2015-05-18 | 2022-05-03 | Ipsen Biopharm Ltd. | Nanoliposomal irinotecan for use in treating small cell lung cancer |
| JP7042739B2 (ja) | 2015-08-20 | 2022-03-28 | イプセン バイオファーム リミティド | 癌処置のためのリポソーム型イリノテカン及びｐａｒｐ阻害薬を使用する併用療法 |
| TW202400181A (zh) | 2015-08-21 | 2024-01-01 | 英商益普生生物製藥有限公司 | 使用包含微脂伊立替康(irinotecan)及奧沙利鉑(oxaliplatin)之組合療法治療轉移性胰臟癌的方法 |
| CN110402163A (zh) | 2016-11-02 | 2019-11-01 | 易普森生物制药有限公司 | 使用包括脂质体伊立替康、奥沙利铂、5-氟尿嘧啶(和甲酰四氢叶酸)的组合疗法治疗胃癌 |
| AU2021258464A1 (en) * | 2020-04-24 | 2023-01-05 | Sanofi | Antitumor combinations containing anti-CEACAM5 antibody conjugates, trifluridine and tipiracil |
| AU2021379882A1 (en) | 2020-11-10 | 2023-06-29 | Sanofi | Ceacam5 antibody-drug conjugate formulation |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6019790A (ja) | 1983-07-14 | 1985-01-31 | Yakult Honsha Co Ltd | 新規なカンプトテシン誘導体 |
| KR100424934B1 (ko) | 1995-03-29 | 2004-07-27 | 다이호야쿠힌고교 가부시키가이샤 | 우라실유도체및이를함유하는항종양효과증강제및항종양제 |
| MX2007003314A (es) * | 2004-09-22 | 2007-08-06 | Pfizer | Combinaciones terapeuticas que comprenden inhibidor de poli(adp-ribosa)polimerasas. |
| CA2594482C (en) * | 2005-01-19 | 2013-10-01 | Zeria Pharmaceutical Co., Ltd. | Antitumor agent |
| US7799783B2 (en) | 2005-01-26 | 2010-09-21 | Taiho Pharmaceutical Co., Ltd. | Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor |
| JP5576591B2 (ja) * | 2005-01-26 | 2014-08-20 | 大鵬薬品工業株式会社 | α，α，α−トリフルオロチミジンとチミジンホスホリラーゼ阻害剤とを配合した抗癌剤 |
| GB0506708D0 (en) * | 2005-04-01 | 2005-05-11 | Queen Mary & Westfield College | Use of calcitonin as combined treatment therapy for the management of inflammatory disease conditions |
| GR20060100144A (el) | 2006-03-03 | 2007-10-17 | Θεραπεια του καρκινου με χρηση οξαλιπλατινης εγκλεισμενης μεσα σε λιποσωματα και απο κοινου εγκλεισμος στο λιποσωμιακο μοριο περισσοτερων απο ενος φαρμακευτικου παρασκευασματος h gene | |
| JP5339373B2 (ja) * | 2006-07-14 | 2013-11-13 | ディーエスエム アイピー アセッツ ビー．ブイ． | 組成物および炎症障害の治療、共治療または予防のためのその使用 |
| JP2011157298A (ja) * | 2010-02-01 | 2011-08-18 | Aska Pharmaceutical Co Ltd | 胃潰瘍治療剤 |
-
2014
- 2014-03-27 JP JP2015508649A patent/JP6002835B2/ja active Active
- 2014-03-27 HU HUE14773638A patent/HUE041687T2/hu unknown
- 2014-03-27 ES ES14773638T patent/ES2702911T3/es active Active
- 2014-03-27 PT PT14773638T patent/PT2979700T/pt unknown
- 2014-03-27 DK DK14773638.3T patent/DK2979700T3/en active
- 2014-03-27 EP EP14773638.3A patent/EP2979700B1/en active Active
- 2014-03-27 SI SI201430982T patent/SI2979700T1/sl unknown
- 2014-03-27 PL PL14773638T patent/PL2979700T3/pl unknown
- 2014-03-27 RS RS20181521A patent/RS58067B1/sr unknown
- 2014-03-27 TW TW103111512A patent/TWI641374B/zh active
- 2014-03-27 HR HRP20182145TT patent/HRP20182145T1/hr unknown
- 2014-03-27 WO PCT/JP2014/058733 patent/WO2014157444A1/ja not_active Ceased
- 2014-03-27 RU RU2015145997A patent/RU2668125C2/ru active
- 2014-03-27 AU AU2014245147A patent/AU2014245147B2/en active Active
- 2014-03-27 LT LTEP14773638.3T patent/LT2979700T/lt unknown
- 2014-03-27 UA UAA201510465A patent/UA117581C2/uk unknown
- 2014-03-27 US US14/779,759 patent/US9616081B2/en active Active
- 2014-03-27 SM SM20180677T patent/SMT201800677T1/it unknown
- 2014-03-27 TR TR2018/19576T patent/TR201819576T4/tr unknown
- 2014-03-27 KR KR1020157026552A patent/KR101848131B1/ko active Active
-
2015
- 2015-10-07 ZA ZA2015/07444A patent/ZA201507444B/en unknown
-
2018
- 2018-12-18 CY CY181101357T patent/CY1120990T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP6002835B2 (ja) | 2016-10-05 |
| DK2979700T3 (en) | 2019-01-21 |
| AU2014245147A1 (en) | 2015-10-15 |
| RU2015145997A (ru) | 2017-05-04 |
| RU2668125C2 (ru) | 2018-09-26 |
| SI2979700T1 (sl) | 2019-01-31 |
| PL2979700T3 (pl) | 2019-03-29 |
| CY1120990T1 (el) | 2019-12-11 |
| US9616081B2 (en) | 2017-04-11 |
| HUE041687T2 (hu) | 2019-05-28 |
| SMT201800677T1 (it) | 2019-01-11 |
| TR201819576T4 (tr) | 2019-01-21 |
| HRP20182145T1 (hr) | 2019-03-08 |
| ES2702911T3 (es) | 2019-03-06 |
| EP2979700A4 (en) | 2016-11-23 |
| RS58067B1 (sr) | 2019-02-28 |
| TW201513864A (zh) | 2015-04-16 |
| EP2979700A1 (en) | 2016-02-03 |
| ZA201507444B (en) | 2017-01-25 |
| US20160082031A1 (en) | 2016-03-24 |
| JPWO2014157444A1 (ja) | 2017-02-16 |
| WO2014157444A1 (ja) | 2014-10-02 |
| UA117581C2 (uk) | 2018-08-27 |
| AU2014245147B2 (en) | 2017-08-31 |
| PT2979700T (pt) | 2018-12-27 |
| KR20150136074A (ko) | 2015-12-04 |
| TWI641374B (zh) | 2018-11-21 |
| KR101848131B1 (ko) | 2018-04-11 |
| EP2979700B1 (en) | 2018-09-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201507444B (en) | Antitumor agent including low dose irinotecan hydrochloride hydrate | |
| ZA201507918B (en) | Nasal administration | |
| IL245211A0 (en) | an inhaler for the medicine | |
| IL243246B (en) | Methods for the treatment of mucosal tumors (polyposis) in the nose through the administration of an il-4r inhibitor | |
| IL246045A0 (en) | Inhalable drugs | |
| IL245157A0 (en) | Antitumor factor | |
| ZA201603463B (en) | An inhalable medicament | |
| ZA201507442B (en) | Antitumor agent including irinotecan hydrochloride hydrate | |
| IL245760A0 (en) | Inhalation medicine | |
| HUE046410T2 (hu) | Eljárások orrpolipózis kezelésére IL-4R-antagonista beadásával | |
| ZA201601152B (en) | Therapeutic agent for dyslipidemia | |
| GB201320786D0 (en) | Medicament |